TWI860392B - (2-乙醯胺基)硫代-β-D-吡喃半乳糖苷衍生物 - Google Patents

(2-乙醯胺基)硫代-β-D-吡喃半乳糖苷衍生物 Download PDF

Info

Publication number
TWI860392B
TWI860392B TW109126970A TW109126970A TWI860392B TW I860392 B TWI860392 B TW I860392B TW 109126970 A TW109126970 A TW 109126970A TW 109126970 A TW109126970 A TW 109126970A TW I860392 B TWI860392 B TW I860392B
Authority
TW
Taiwan
Prior art keywords
pyran
tetrahydro
triazol
thio
hydroxymethyl
Prior art date
Application number
TW109126970A
Other languages
English (en)
Chinese (zh)
Other versions
TW202120101A (zh
Inventor
馬汀 波利
丹尼爾 布爾
約翰 加菲歐
康妮雅 克索湯米
路伯斯 雷曼
柯奈利亞 宗布倫
Original Assignee
瑞士商愛杜西亞製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商愛杜西亞製藥有限公司 filed Critical 瑞士商愛杜西亞製藥有限公司
Publication of TW202120101A publication Critical patent/TW202120101A/zh
Application granted granted Critical
Publication of TWI860392B publication Critical patent/TWI860392B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
TW109126970A 2019-08-09 2020-08-07 (2-乙醯胺基)硫代-β-D-吡喃半乳糖苷衍生物 TWI860392B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2019071399 2019-08-09
WOPCT/EP2019/071399 2019-08-09

Publications (2)

Publication Number Publication Date
TW202120101A TW202120101A (zh) 2021-06-01
TWI860392B true TWI860392B (zh) 2024-11-01

Family

ID=71944145

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109126970A TWI860392B (zh) 2019-08-09 2020-08-07 (2-乙醯胺基)硫代-β-D-吡喃半乳糖苷衍生物

Country Status (9)

Country Link
US (1) US12410208B2 (enExample)
EP (1) EP4010348B1 (enExample)
JP (1) JP7612663B2 (enExample)
KR (1) KR102863667B1 (enExample)
CN (1) CN114206892A (enExample)
CA (1) CA3147078A1 (enExample)
ES (1) ES2974680T3 (enExample)
TW (1) TWI860392B (enExample)
WO (1) WO2021028323A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114206893A (zh) 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CN114585619B (zh) 2019-08-29 2024-09-27 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
US12312362B2 (en) 2020-10-06 2025-05-27 Idorsia Pharmaceuticals Ltd Spiro derivatives of Alpha-D-galactopyranosides
EP4237419A1 (en) 2020-11-02 2023-09-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
CN116806219A (zh) 2021-02-09 2023-09-26 爱杜西亚药品有限公司 羟基杂环烷-氨甲酰基衍生物
RS67032B1 (sr) 2021-03-03 2025-08-29 Idorsia Pharmaceuticals Ltd Alfa-d-galaktopiranozidni derivati supstituisani triazolil-metilom
WO2022189459A2 (en) * 2021-03-10 2022-09-15 Galecto Biotech Ab Novel galactoside inhibitor of galectins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018011094A1 (en) * 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
WO2019089080A1 (en) * 2017-10-31 2019-05-09 Galectin Sciences, Llc Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
DK2906227T3 (en) 2012-10-10 2018-12-10 Galectin Therapeutics Inc GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy
CN104755088A (zh) 2012-10-31 2015-07-01 格莱克特生物技术公司 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用
EP2919802A4 (en) 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
CA2970062C (en) 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
PL3456717T3 (pl) 2015-07-06 2021-10-25 Gilead Sciences, Inc. Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej
RU2724345C2 (ru) * 2015-10-09 2020-06-23 Галапагос Нв N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
KR20200015528A (ko) 2017-05-12 2020-02-12 갈랙틴 사이언시즈, 엘엘씨 전신 인슐린 내성 질환의 치료용 화합물 및 그의 용도
EP3621973A4 (en) 2017-05-12 2021-10-27 Galectin Sciences, LLC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND USES THEREOF
WO2019067702A1 (en) 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
US11072626B2 (en) 2017-10-11 2021-07-27 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
CN113286632A (zh) 2018-10-15 2021-08-20 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂前药
JP2022508720A (ja) 2018-10-15 2022-01-19 ガレクト バイオテック エービー ガレクチンのガラクトシド阻害剤
WO2020104335A1 (en) 2018-11-21 2020-05-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
US12269819B2 (en) 2019-04-10 2025-04-08 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
JP7674276B2 (ja) 2019-07-03 2025-05-09 ガレクト バイオテック エービー ガレクチンの新規なガラクトシド阻害剤
WO2021004940A1 (en) 2019-07-05 2021-01-14 Galecto Biotech Ab Novel galactoside inhibitor of galectins
CN114206893A (zh) 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CN114585619B (zh) 2019-08-29 2024-09-27 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
US12312362B2 (en) 2020-10-06 2025-05-27 Idorsia Pharmaceuticals Ltd Spiro derivatives of Alpha-D-galactopyranosides
EP4237419A1 (en) 2020-11-02 2023-09-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
CN116806219A (zh) 2021-02-09 2023-09-26 爱杜西亚药品有限公司 羟基杂环烷-氨甲酰基衍生物
RS67032B1 (sr) 2021-03-03 2025-08-29 Idorsia Pharmaceuticals Ltd Alfa-d-galaktopiranozidni derivati supstituisani triazolil-metilom

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018011094A1 (en) * 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
WO2019089080A1 (en) * 2017-10-31 2019-05-09 Galectin Sciences, Llc Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof

Also Published As

Publication number Publication date
CN114206892A (zh) 2022-03-18
CA3147078A1 (en) 2021-02-18
TW202120101A (zh) 2021-06-01
US20220306674A1 (en) 2022-09-29
US12410208B2 (en) 2025-09-09
EP4010348B1 (en) 2023-12-20
ES2974680T3 (es) 2024-07-01
EP4010348A1 (en) 2022-06-15
KR102863667B1 (ko) 2025-09-23
WO2021028323A1 (en) 2021-02-18
JP2022543859A (ja) 2022-10-14
JP7612663B2 (ja) 2025-01-14
KR20220044573A (ko) 2022-04-08

Similar Documents

Publication Publication Date Title
TWI860392B (zh) (2-乙醯胺基)硫代-β-D-吡喃半乳糖苷衍生物
TWI864071B (zh) 2-羥環烷-1-胺甲醯基衍生物
TWI873165B (zh) (雜)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
JP7844491B2 (ja) ヒドロキシヘテロシクロアルカン－カルバモイル誘導体
JP7834746B2 (ja) ガレクチン－３を阻害する２－ヒドロキシシクロアルカン－１－カルバモイル誘導体
TWI890869B (zh) α-D-吡喃半乳糖苷之螺衍生物
EA048291B1 (ru) 2-гидроксициклоалкан-1-карбамоильные производные